SCYNEXIS INC

Listed Company

SCYXCIK 0001178253NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$20.60M

Net Income

$-8.61M

Total Assets

$59.03M

Equity

$49.38M

Shares Out

44.66M

Op. Cash Flow

$-5.28M

Business

SCYNEXIS INC is a biopharmaceutical company developing novel antifungal medicines based on its proprietary triterpenoid “fungerp” platform. Its main products include ibrexafungerp (commercial name BREXAFEMME), an orally administered non-azole antifungal approved for vulvovaginal candidiasis and RVVC, and SCY-247, a second‑generation fungerp in clinical development. The company operates through drug discovery and development activities and through licensing and collaboration arrangements with partners such as GSK, Hansoh and R‑Pharm. Its products and trials are pursued via global regulatory, clinical and commercial channels across multiple international markets.

Summary from filing dated 2025-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	21	4	140	5	13
Research and development	22	26	31	27	24
Selling, general and administrative	14	14	21	63	50
Total operating expenses	37	41	67	91	74
Loss from operations	−16	−37	73	−86	−61
Amortization of debt issuance costs and discount	312,000	2	3	2	1
Interest income	−2	−4	−4	−1	−24,000
Interest expense	173,000	828,000	3	—	—
Other income	0	−235,000	0	−3,000	−13,000
Warrant liability fair value adjustment	−6	−14	3	−22	−30
Derivative liability fair value adjustment	0	−196,000	154,000	−1	−1
Total other income	−7	−16	5	−18	−25
Loss before taxes	−9	−21	67	−68	−36
Income tax expense	0	−200,000	−100,000	5	3
Net loss	−9	−21	67	−63	−33
Net loss per share - basic	−0.17	−0.44	1.4	−1.47	−1.25
Net loss per share - diluted	−0.17	−0.44	1.39	−1.47	−1.25
Weighted average common shares outstanding - basic	50	49	48	43	26
Weighted average common shares outstanding - diluted	50	49	48	43	26

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	21	16	34	46	104
Short-term investments (Note 3)	19	43	40	28	0
Prepaid expenses and other current assets (Note 4)	263,000	2	6	3	4
License agreement receivable	0	753,000	2	0	—
License agreement contract asset	0	10	19	0	—
Restricted cash	80,000	435,000	380,000	55,000	0
Total current assets	40	72	102	79	109
Investments (Note 3)	16	16	24	0	—
Deferred offering costs	533,000	417,000	175,000	73,000	150,000
Restricted cash	109,000	109,000	163,000	163,000	218,000
Operating lease right-of-use asset (Note 6)	2	2	2	3	3
Total assets	59	91	128	88	120
Accounts payable	2	5	7	6	8
Accrued expenses (Note 5)	3	4	7	6	6
Deferred revenue, current portion	200,000	2	1	0	—
Operating lease liability, current portion (Note 6)	483,000	407,000	340,000	282,000	70,000
Convertible debt and derivative liability (Note 6)	0	14	0	—	—
Total current liabilities	6	24	16	18	14
Deferred revenue	0	1	3	0	—
Warrant liability	2	8	22	19	18
Operating lease liability (Note 6)	2	2	3	3	3
Total liabilities	10	36	55	85	79
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2025 and 2024; 0 shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value, 150,000,000 shares authorized as of December 31, 2025 and 2024; 43,541,510 and 37,973,991 shares issued and outstanding as of December 31, 2025, and 2024, respectively	46,000	41,000	40,000	36,000	32,000
Additional paid-in capital	434	432	428	425	401
Accumulated deficit	−385	−377	−355	−422	−359
Total stockholders equity	49	55	73	3	41
Total liabilities and stockholders equity	59	91	128	88	120

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net (loss) income	−9	−21	67	−63	−33
Stock-based compensation expense	3	3	3	4	2
Accretion of investment discount	−474,000	−1	−1	−309,000	0
Noncash operating lease expense for right-of-use asset	326,000	272,000	230,000	207,000	198,000
Prepaid expenses and other current assets, deferred costs, and other	2	3	−3	2	2
License agreement contract asset	10	10	−19	0	—
License agreement receivable	753,000	2	−2	0	—
Accounts payable	−2	−3	1	−1	3
Accrued expenses	−1	−4	2	−70,000	—
Deferred revenue	−3	−979,000	4	0	—
Other liabilities and other	−407,000	−339,000	−6	2	—
Net cash used in operating activities	−5	−24	60	−80	−55
Purchase of investments	−19	−36	−85	−27	0
Maturity of investments	43	43	51	0	—
Net cash provided by investing activities	24	6	−35	−27	−1
Proceeds from common stock issued	5,000	0	0	47	39
Payment of convertible debt	−14	0	—	—	—
Payments of deferred offering costs	−226,000	−195,000	−135,000	—	—
Proceeds from employee stock purchase plan issuances	51,000	56,000	42,000	18,000	22,000
Net cash used in financing activities	−14	−139,000	−37	49	67
Net increase (decrease) in cash, cash equivalents, and restricted cash	5	−18	−11	−59	11
Cash paid for interest	420,000	840,000	3	5	2
Cash received for interest	2	3	4	1	24,000
Deferred offering and issuance costs included in accounts payable	0	110,000	40,000	0	430,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro